Prostate Specific Antigen News and Research

RSS

Patients with advanced cancer undergo common non-beneficial cancer screening tests

A sizeable proportion of patients with advanced cancer and a life expectancy of only a few years continue to undergo common cancer screening tests that are unlikely to provide meaningful benefit, according to a study in the October 13 issue of JAMA.

13 Oct 2010

Cancer patients getting unnecessary tests: Study

US researchers revealed that many cancer patients with only a few years to live often continue to get routine mammograms or blood tests for prostate cancer even though they are not likely to live long enough to benefit from them. This not only wastes money but also exposes patients to unnecessary worry and distress.

12 Oct 2010

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

11 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

New imaging technique may help in early detection of prostate cancer

Prostate cancer -- the most common cancer afflicting American men -- may be effectively diagnosed at an early stage without ionizing radiation, using a non-invasive imaging technique known as contrast-enhanced ultrasound (CEUS), according to a report announced late last week at the 25th Annual Advances in Contrast Ultrasound - ICUS Bubble Conference in Chicago.

8 Oct 2010

Prostate cancer updates

Scientists have found that genetic variations for an enzyme involved in cell energy metabolism may increase the risk of prostate cancer. This variation in genes may impair the enzyme phosphodiesterase 11A (PDE11A), which helps regulate cells' responses to hormones and other signals, according to the U.S. National Institute of Child Health and Human Development researchers and colleagues.

8 Oct 2010

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Sanofi-aventis announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana (cabazitaxel) Injection, was published in the October 2, 2010 print edition of The Lancet in an article titled "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

4 Oct 2010

AccuPSA test for detecting prostate cancer recurrence

A new test could reliably detect early increases in prostate specific antigen (PSA) levels a biomarker commonly used to measure the recurrence of prostate cancer in men who have undergone prostate cancer treating surgery. Earlier detection of these rising levels would allow men with cancer recurrence to undergo earlier, more effective treatment for potentially better outcomes.

30 Sep 2010

Radical prostatectomy increases survival rate in prostate cancer patients: Study

In the largest, most modern, single-institution study of its kind, Mayo Clinic urologists mined a long-term data registry for survival rates of patients who underwent radical prostatectomy for localized prostate cancer. The findings are being presented at the North Central Section of the American Urological Association's 84th Annual Meeting in Chicago.

30 Sep 2010

Researchers discover new diagnostic test for prostate cancer

Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy.

From Oxford Gene Technology 29 Sep 2010

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC).

27 Sep 2010

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a randomized, controlled, investigator sponsored Phase 2 trial of OGX-427 in men with metastatic prostate cancer.

27 Sep 2010

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Gen-Probe announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its PROGENSA® PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer.

22 Sep 2010

CINJ experts available for discussion during National Prostate Cancer Awareness Month

The Cancer Institute of New Jersey (CINJ) is making experts available to discuss the risks, treatments and prevention options surrounding prostate cancer during September, which is National Prostate Cancer Awareness Month. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

15 Sep 2010

TNS NIPO study underlines need for wide-scale, reliable prostate cancer screening

A recent TNS NIPO survey, on behalf of the Dutch Association of Urology (NVU) and the European Association of Urology (EAU), showed that almost four out of 10 Dutch men of 50 years and older suffer, or have suffered, from urinary complaints. The same number of men also said in the same survey they are worried that they may have prostate cancer.

15 Sep 2010

Men with low PSA level does not benefit further treatment: Study

Men aged 55 to 74 years who have low baseline blood levels of prostate specific antigen (PSA) are not likely to benefit from further screening and treatment. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The aim of the study is to help physicians and patients weigh the pros and cons of prostate cancer screening and early detection.

13 Sep 2010

Measuring PSA levels effective in detecting prostate cancer: Study

A new multinational study suggests that regular blood testing to measure levels of prostate specific antigen (PSA) is more effective at detecting prostate cancer in men with a genetic predisposition to the disease.

13 Sep 2010

Experts advise men to maintain record of prostate specific antigen test results for risk detection

Experts at The University of Texas MD Anderson Cancer Center advise men to keep a record of their prostate specific antigen (PSA) test results to help determine if they are at increased risk for prostate cancer.

10 Sep 2010

Virginia G. Piper Cancer Center at Scottsdale Healthcare offers free prostate cancer screenings

Recognizing that early detection can save lives, the Virginia G. Piper Cancer Center at Scottsdale Healthcare is offering free prostate cancer screenings from 8:30 a.m.-12 p.m. on Saturday, Sept. 11.

3 Sep 2010

PCEC coordinates free or low-cost prostate cancer screenings as part of PCAW

A council of leading prostate cancer experts is working to protect the lives of American men by providing lifesaving prostate cancer screenings. The Prostate Conditions Education Council – a national organization committed to men's health and a leader in prostate cancer screening – is once again coordinating free or low-cost screenings as part of its national Prostate Cancer Awareness Week to help encourage men to protect their health.

30 Aug 2010

Prostate Specific Antigen News and Research

Patients with advanced cancer undergo common non-beneficial cancer screening tests

Cancer patients getting unnecessary tests: Study

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Abiraterone Phase III clinical data to be presented at ESMO meeting

New imaging technique may help in early detection of prostate cancer

Prostate cancer updates

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

AccuPSA test for detecting prostate cancer recurrence

Radical prostatectomy increases survival rate in prostate cancer patients: Study

Researchers discover new diagnostic test for prostate cancer

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

CINJ experts available for discussion during National Prostate Cancer Awareness Month

TNS NIPO study underlines need for wide-scale, reliable prostate cancer screening

Men with low PSA level does not benefit further treatment: Study

Measuring PSA levels effective in detecting prostate cancer: Study

Experts advise men to maintain record of prostate specific antigen test results for risk detection

Virginia G. Piper Cancer Center at Scottsdale Healthcare offers free prostate cancer screenings

PCEC coordinates free or low-cost prostate cancer screenings as part of PCAW

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News